OBJECTIVES: Surveillance after resection of solitary fibrous tumours of the pleura (SFTP) remains undefined. This study reviews our experience with surgical treatment of SFTP to determine the specific risk factors to predict recurrence. METHODS: A retrospective review of 59 patients surgically treated for SFTP during the years 1977-2010 was conducted. Clinico-pathological factors for recurrence were analysed by Kaplan-Meier and Cox proportional hazard methods. RESULTS: The mean age was 57 ± 14 years. There were 32 (54%) men. Among 32 (54%) symptomatic patients, chest pain (22%), cough (19%) and dyspnoea (17%) were most frequent. The mean tumour size was 7.3 ± 6.7 cm, and 14 patients had SFTPs larger than 10 cm. An SFTP was pedunculated in 38 (67%) cases and had a visceral origin in 40 (68%). Paraneoplastic syndromes were observed in 3 (5%) patients. On histopathologic analysis, 4 (7%) presented ≥ 4 mitosis/10 high-power fields (HPFs), 8 (15%) atypia, 14 (24%) hypercellularity and 6 (10%) necrosis. After a mean follow-up of 8.8 ± 7.0 years, we observed 8 (14%) recurrences; median time to recurrence was 6 years (range 2-16 years). Two (3%) patients received adjuvant therapy. We constructed a predictive score for recurrence by assigning one point to each of the six variables: parietal (vs visceral) pleural origin, sessile (vs pedunculated) morphology, size >10 cm (vs <10 cm), the presence of hypercellularity, necrosis and mitotic activity ≥ 4/HPF (vs <4). A score of ≥ 3 best predicted recurrence (sensitivity: 100%, specificity: 92%, area under receiver operating characteristic curve = 0.966, P < 0.0001). With a score of ≥ 3, recurrence-free survival was 80%, 69, 23 and 23% at 3, 5, 10 and 15 years, whereas a score of <3 was 100% up to 15 years. Our scoring system was superior in predicting malignant behaviour and recurrence compared with England's criteria or de Perrot staging. CONCLUSIONS: The proposed scoring system is simple, easily obtained from existing pathological description and reliably predicts recurrence in this patient population harbouring SFTP. The SFTP score may stratify patient risk and guide postoperative surveillance. We recommend validation in additional clinical series.
OBJECTIVES: Surveillance after resection of solitary fibrous tumours of the pleura (SFTP) remains undefined. This study reviews our experience with surgical treatment of SFTP to determine the specific risk factors to predict recurrence. METHODS: A retrospective review of 59 patients surgically treated for SFTP during the years 1977-2010 was conducted. Clinico-pathological factors for recurrence were analysed by Kaplan-Meier and Cox proportional hazard methods. RESULTS: The mean age was 57 ± 14 years. There were 32 (54%) men. Among 32 (54%) symptomatic patients, chest pain (22%), cough (19%) and dyspnoea (17%) were most frequent. The mean tumour size was 7.3 ± 6.7 cm, and 14 patients had SFTPs larger than 10 cm. An SFTP was pedunculated in 38 (67%) cases and had a visceral origin in 40 (68%). Paraneoplastic syndromes were observed in 3 (5%) patients. On histopathologic analysis, 4 (7%) presented ≥ 4 mitosis/10 high-power fields (HPFs), 8 (15%) atypia, 14 (24%) hypercellularity and 6 (10%) necrosis. After a mean follow-up of 8.8 ± 7.0 years, we observed 8 (14%) recurrences; median time to recurrence was 6 years (range 2-16 years). Two (3%) patients received adjuvant therapy. We constructed a predictive score for recurrence by assigning one point to each of the six variables: parietal (vs visceral) pleural origin, sessile (vs pedunculated) morphology, size >10 cm (vs <10 cm), the presence of hypercellularity, necrosis and mitotic activity ≥ 4/HPF (vs <4). A score of ≥ 3 best predicted recurrence (sensitivity: 100%, specificity: 92%, area under receiver operating characteristic curve = 0.966, P < 0.0001). With a score of ≥ 3, recurrence-free survival was 80%, 69, 23 and 23% at 3, 5, 10 and 15 years, whereas a score of <3 was 100% up to 15 years. Our scoring system was superior in predicting malignant behaviour and recurrence compared with England's criteria or de Perrot staging. CONCLUSIONS: The proposed scoring system is simple, easily obtained from existing pathological description and reliably predicts recurrence in this patient population harbouring SFTP. The SFTP score may stratify patient risk and guide postoperative surveillance. We recommend validation in additional clinical series.
Authors: Benoit Lahon; Olaf Mercier; Elie Fadel; Maria Rosa Ghigna; Boriana Petkova; Sacha Mussot; Dominique Fabre; Thierry Le Chevalier; Philippe Dartevelle Journal: Ann Thorac Surg Date: 2012-06-13 Impact factor: 4.330
Authors: Jason S Gold; Cristina R Antonescu; Cristina Hajdu; Cristina R Ferrone; Mustafa Hussain; Jonathan J Lewis; Murray F Brennan; Daniel G Coit Journal: Cancer Date: 2002-02-15 Impact factor: 6.860
Authors: Pierre Magdeleinat; Marco Alifano; Antonio Petino; Jean Philippe Le Rochais; Elisabeth Dulmet; Françoise Galateau; Philippe Icard; Jean François Regnard Journal: Eur J Cardiothorac Surg Date: 2002-06 Impact factor: 4.191
Authors: Melissa L Rosado-de-Christenson; Gerald F Abbott; H Page McAdams; Teri J Franks; Jeffrey R Galvin Journal: Radiographics Date: 2003 May-Jun Impact factor: 5.333
Authors: Tatiana Georgiesh; Ninna Aggerholm-Pedersen; Patrick Schöffski; Yifan Zhang; Andrea Napolitano; Judith V M G Bovée; Åse Hjelle; Gordon Tang; Mateusz Spalek; Margherita Nannini; David Swanson; Thomas Baad-Hansen; Raf Sciot; Asle C Hesla; Paul Huang; Desiree Dorleijn; Hans Kristian Haugland; Maribel Lacambra; Jacek Skoczylas; Maria A Pantaleo; Rick L Haas; Leonardo A Meza-Zepeda; Florian Haller; Anna M Czarnecka; Herbert Loong; Nina L Jebsen; Michiel van de Sande; Robin L Jones; Felix Haglund; Iris Timmermans; Akmal Safwat; Bodil Bjerkehagen; Kjetil Boye Journal: Br J Cancer Date: 2022-08-27 Impact factor: 9.075
Authors: Armita Bahrami; Seungjae Lee; Inga-Marie Schaefer; Jennifer M Boland; Kurt T Patton; Stanley Pounds; Christopher D Fletcher Journal: Mod Pathol Date: 2016-08-26 Impact factor: 7.842
Authors: Mª A Vaz Salgado; M Soto; Mª E Reguero; G Muñoz; A Cabañero; I Gallego; S Resano; F Longo; A Madariaga; A Gomez; A Carrato Journal: Clin Transl Oncol Date: 2016-09-07 Impact factor: 3.405
Authors: Luis F Tapias; Olaf Mercier; Maria R Ghigna; Benoit Lahon; Hang Lee; Douglas J Mathisen; Philippe Dartevelle; Michael Lanuti Journal: Chest Date: 2015-01 Impact factor: 9.410
Authors: Mert Saynak; Nirmal K Veeramachaneni; Jessica L Hubbs; Dilruba Okumuş; Lawrence B Marks Journal: Balkan Med J Date: 2017-04-06 Impact factor: 2.021
Authors: Lorenzo Rinaldo; Sarah Chao Ying Xu; Scott D Eggers; Diva R Salomão; John J Chen; Aditya Raghunathan Journal: Ocul Oncol Pathol Date: 2017-12-16
Authors: Bahil Ghanim; Sebastian Hess; Pietro Bertoglio; Ali Celik; Aynur Bas; Felicitas Oberndorfer; Franca Melfi; Alfredo Mussi; Walter Klepetko; Christine Pirker; Walter Berger; Imrich Harmati; Attila Farkas; Hendrik Jan Ankersmit; Balazs Dome; Janos Fillinger; Clemens Aigner; Balazs Hegedus; Ferenc Renyi-Vamos; György Lang Journal: Sci Rep Date: 2017-10-02 Impact factor: 4.379